🇺🇸 FDA
Pipeline program

SN301A

SN301A-001

Phase 1 mab active

Quick answer

SN301A for Hepatocellular Carcinoma (HCC) is a Phase 1 program (mab) at Senti Biosciences Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Senti Biosciences Holdings
Indication
Hepatocellular Carcinoma (HCC)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials